Reaction
Immune-Mediated Hypothyroidism reporting signals
As of the last recalculation, Immune-Mediated Hypothyroidism appears in 1,061 FAERS reports alongside 19 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 329.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 664 | 329.2 | 331.3 |
| Ipilimumab | 200 | 111.8 | 112.3 |
| Nivolumab | 303 | 85.7 | 85.9 |
| Lenvatinib | 94 | 61.6 | 61.8 |
| Carboplatin | 265 | 54.2 | 54.3 |
| Pemetrexed | 53 | 51.0 | 51.1 |
| Paclitaxel (Aibumin-Bound) | 161 | 45.1 | 45.2 |
| Durvalumab | 41 | 41.1 | 41.2 |
| Pemetrexed Disodium | 71 | 39.1 | 39.2 |
| Paclitaxel | 167 | 39.1 | 39.1 |
| Axitinib | 18 | 18.4 | 18.4 |
| Cisplatin | 62 | 16.5 | 16.5 |
| Aprepitant | 13 | 14.0 | 14.0 |
| Gemcitabine Hydrochloride | 32 | 12.2 | 12.2 |
| Fosaprepitant Dimeglumine | 7 | 10.0 | 10.1 |
| Cabozantinib | 23 | 9.6 | 9.6 |
| Granisetron | 5 | 9.4 | 9.4 |
| Atezolizumab | 18 | 9.2 | 9.2 |
| Encorafenib | 3 | 6.0 | 6.0 |